Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (02171) experienced a significant stock increase of over 9%, reaching HKD 17.66 with a trading volume of HKD 11.95 million, following the announcement of positive clinical trial results for its CAR-T cell therapy targeting pancreatic cancer [1] Group 1: Clinical Trial Results - Kintor announced that the results of its Phase Ib registration clinical trial for the CAR-T cell product CT053 (Zevoracel) targeting BCMA in the treatment of pancreatic cancer have been presented at the 2025 European Society for Medical Oncology (ESMO) annual meeting [1] - This trial is noted as the first global study exploring CAR-T cell therapy for adjuvant treatment in solid tumors, marking a significant milestone in the field [1] Group 2: Insurance and Reimbursement Developments - On September 20, the National Healthcare Security Administration announced the completion of expert review work for the first version of the commercial insurance innovative drug catalog [1] - Kintor's Zevoracel, along with four other CAR-T drugs, successfully passed the expert review and is expected to be included in this year's basic medical insurance catalog and commercial insurance innovative drug catalog [1]
港股异动 | 科济药业-B(02171)早盘涨超9% 公司在2025年ESMO年会上呈列泽沃基奥仑赛注射液研究成果